Evidence map›Paper›PMID 40673302›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2025

[The TGF‑β/miR-23a-3p/IRF1 axis mediates immune escape of hepatocellular carcinoma by inhibiting major histocompatibility complex class I].

Ying Yu, Li Tu, Yang Liu, Xueyi Song, Qianqian Shao, Xiaolong Tang

Abstract readEnglish Abstract
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying YuSchool of Medicine, Anhui University of Science and Technology, Huainan 232001, China.
Li TuSchool of Medicine, Anhui University of Science and Technology, Huainan 232001, China.
Yang LiuSchool of Medicine, Anhui University of Science and Technology, Huainan 232001, China.
Xueyi SongSchool of Medicine, Anhui University of Science and Technology, Huainan 232001, China.
Qianqian ShaoSchool of Medicine, Anhui University of Science and Technology, Huainan 232001, China.
Xiaolong TangSchool of Medicine, Anhui University of Science and Technology, Huainan 232001, China.

Funding

National Natural Science Foundation of China 82071862
6 · The paper itself

Abstract

objectivesTo investigate the mechanism by which transforming growth factor‑β (TGF‑β) regulates major histocompatibility complex class I (MHC-I) expression in hepatocellular carcinoma (HCC) cells and its role in immune evasion of HCC.

methodsHCC cells treated with TGF‑β alone or in combination with SB-431542 (a TGF-β type I receptor inhibitor) were examined for changes in MHC-I expression using RT-qPCR and Western blotting. A RNA interference experiment was used to explore the role of miR-23a-3p/IRF1 signaling in TGF‑β‑mediated regulation of MHC-I. HCC cells with different treatments were co-cultured with human peripheral blood mononuclear cells (PBMCs), and the changes in HCC cell proliferation was assessed using CCK-8 and colony formation assays. T-cell cytotoxicity in the co-culture systems was assessed with lactate dehydrogenase (LDH) release and JC-1 mitochondrial membrane potential assays, and T-cell activation was evaluated by flow cytometric analysis of CD69 cells and ELISA for TNF-α secretion.

resultsTGF‑β treatment significantly suppressed MHC-I expression in HCC cells and reduced T-cell activation, leading to increased tumor cell proliferation and decreased HCC cell death in the co-culture systems. Mechanistically, TGF-β upregulated miR-23a-3p, which directly targeted IRF1 to inhibit MHC-I transcription. Overexpression of miR-23a-3p phenocopied TGF‑β‑induced suppression of IRF1 and MHC-I.

conclusionsWe reveal a novel immune escape mechanism of HCC, in which TGF‑β attenuates T cell-mediated antitumor immunity by suppressing MHC-I expression through the miR-23a-3p/IRF1 signaling axis.

Indexed as

Carcinoma, HepatocellularHistocompatibility Antigens Class IInterferon Regulatory Factor-1Liver NeoplasmsMicroRNAsTransforming Growth Factor betaTumor EscapeCell Line, TumorCoculture TechniquesHumansSignal TransductionHistocompatibility Antigens Class IInterferon Regulatory Factor-1IRF1 protein, humanMicroRNAsMIRN23a microRNA, humanTransforming Growth Factor betaliver cancer cellsmajor histocompatibility complex class Itransforming growth factor-βtumor immune escape

Identifiers

PMID40673302
PMCPMC12268904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.